BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7653449)

  • 1. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.
    Am J Cardiol; 1995 Sep; 76(7):485-91. PubMed ID: 7653449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
    Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group.
    J Clin Epidemiol; 1992 Aug; 45(8):849-60. PubMed ID: 1624967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
    L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
    Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
    J Clin Epidemiol; 1995 Dec; 48(12):1441-52. PubMed ID: 8543958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
    Shepherd J
    Am J Cardiol; 1995 Sep; 76(9):113C-117C. PubMed ID: 7572679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
    Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
    N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
    Am J Cardiol; 1997 Mar; 79(6):756-62. PubMed ID: 9070554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
    Shepherd J
    Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
    Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
    Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study.
    Brouilette SW; Moore JS; McMahon AD; Thompson JR; Ford I; Shepherd J; Packard CJ; Samani NJ;
    Lancet; 2007 Jan; 369(9556):107-14. PubMed ID: 17223473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [WOSCOPS [West of Scotland Coronary Prevention Study]].
    Furutani N; Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():387-92. PubMed ID: 11347100
    [No Abstract]   [Full Text] [Related]  

  • 19. A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.
    Ford I; Blauw GJ; Murphy MB; Shepherd J; Cobbe SM; Bollen EL; Buckley BM; Jukema JW; Hyland M; Gaw A; Lagaay AM; Perry IJ; Macfarlane P; Norrie J; Meinders AE; Sweeney BJ; Packard CJ; Westendorp RG; Twomey C; Stott DJ;
    Curr Control Trials Cardiovasc Med; 2002 May; 3(1):8. PubMed ID: 12097148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
    Hay JW; Yu WM; Ashraf T
    Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.